Post-operative flank irradiation using conformal versus highly conformal radiotherapy techniques for paediatric renal tumours: Results from the French registry PediaRT.
flank irradiation
highly conformal radiotherapy
intensity-modulated radiotherapy
locoregional failure
paediatric renal tumour
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
11
07
2023
received:
03
04
2023
accepted:
05
08
2023
medline:
23
10
2023
pubmed:
15
8
2023
entrez:
15
8
2023
Statut:
ppublish
Résumé
Three-dimensional conformal RT (3D-RT) techniques are gold standard for post-operative flank radiotherapy (RT) in paediatric renal tumours. Recently, highly conformal RT (HC-RT) techniques have been implemented without comparative clinical data. The main objective of this multicentre study was to compare locoregional control (LRC) in children treated either with HC-RT or 3D-RT techniques. Patients treated with post-operative flank RT for renal tumour registered in the national cohort PediaRT between March 2013 and September 2019 were included. Treatment and follow-up data, including toxicities and outcomes, were retrieved from the database. LRC was calculated, and dose reconstruction was performed in case of an event. Seventy-nine patients were included. Forty patients were treated with HC-RT and 39 with 3D-RT. Median follow-up was 4.5 years. Three patients had locoregional failure (LRF; 4%). HC-RT was not associated with a higher risk of LRF. Three-year LRC were 97.4% and 94.7% in the HC-RT and 3D-RT groups, respectively. The proportion of planning target volumes receiving 95% or more of the prescribed dose did not significantly differ between both groups (HC-RT 88%; 3D-RT 69%; p = .05). HC-RT was better achieving dose constraints, and a significant mean dose reduction was observed in the peritoneal cavity and pancreas associated with lower incidence of acute gastrointestinal toxicity. LRF after post-operative flank RT for renal tumours was rare and did not increase using HC-RT versus 3D-RT techniques. Dose to the pancreas and the peritoneal cavity, as well as acute toxicity, were reduced with HC-RT compared to 3D-RT.
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30627Informations de copyright
© 2023 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69:7-34. doi:10.3322/caac.21551
Steliarova-Foucher E, Colombet M, Ries LAG, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017;18:719-731. doi:10.1016/S1470-2045(17)30186-9
INCA-Les cancers en France n.d. INCA. Accessed August 23, 2022. https://www.e-cancer.fr/ressources/cancers_en_france/
Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15:35-47. doi:10.1016/S1470-2045(13)70548-5
Groenendijk A, Spreafico F, de Krijger RR, et al. Prognostic factors for Wilms tumor recurrence: a review of the literature. Cancers. 2021;13:3142. doi:10.3390/cancers13133142
Chagtai T, Zill C, Dainese L, et al. Gain of 1q as a prognostic biomarker in Wilms tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 trial: a SIOP Renal Tumours Biology Consortium study. J Clin Oncol. 2016;34:3195-3203. doi:10.1200/JCO.2015.66.0001
Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23:7312-7321. doi:10.1200/JCO.2005.01.2799
Nakata K, Colombet M, Stiller CA, Pritchard-Jones K, Steliarova-Foucher E, IICC-3 Contributors. Incidence of childhood renal tumours: an international population-based study. Int J Cancer. 2020;147:3313-3327. doi:10.1002/ijc.33147
Dome JS, Graf N, Geller JI, et al. Advances in Wilms tumor treatment and biology: progress through international collaboration. J Clin Oncol. 2015;33:2999-3007. doi:10.1200/JCO.2015.62.1888
Brok J, Lopez-Yurda M, Tinteren HV, et al. Relapse of Wilms’ tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group-International Society of Paediatric Oncology Wilms’ tumour protocol database. Lancet Oncol. 2018;19:1072-1081. doi:10.1016/S1470-2045(18)30293-6
Spreafico F, Fernandez CV, Brok J, et al. Wilms tumour. Nat Rev Dis Primers. 2021;7:75. doi:10.1038/s41572-021-00308-8
Malogolowkin M, Spreafico F, Hol JA, et al. Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. Nat Rev Urol. 2017;14:743-752. doi:10.1038/nrurol.2017.163
the International Society of Paediatric Oncology - Renal Tumour Study Group (SIOP-RTSG), van den Heuvel-Eibrink MM, Hol JA, et al. Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. Nat Rev Urol. 2017;14:743-752. doi:10.1038/nrurol.2017.163
Pritchard-Jones K, Bergeron C, de Camargo B, et al. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet North Am Ed. 2015;386:1156-1164. doi:10.1016/S0140-6736(14)62395-3
van Dijk IWEM, Oldenburger F, Cardous-Ubbink MC, et al. Evaluation of late adverse events in long-term Wilms’ tumor survivors. I J Radiat Oncol Biol Phys. 2010;78:370-378. doi:10.1016/j.ijrobp.2009.08.016
Jouglar E, Laprie A, Isfan F, et al. Locoregional failure after postoperative flank irradiation for nephroblastoma: results from the French cohort of the SIOP-2001 trial. Pediatr Blood Cancer. 2022;69(12):e29950. doi:10.1002/pbc.29950
Mul J, Seravalli E, Bosman ME, et al. Estimated clinical benefit of combining highly conformal target volumes with volumetric-modulated arc therapy (VMAT) versus conventional flank irradiation in pediatric renal tumors. Clin Transl Radiat Oncol. 2021;29:20-26. doi:10.1016/j.ctro.2021.04.007
Jouglar E, Wagner A, Delpon G, et al. Can we spare the pancreas and other abdominal organs at risk? A comparison of conformal radiotherapy, helical tomotherapy and proton beam therapy in pediatric Irradiation. PLoS One. 2016;11:e0164643. doi:10.1371/journal.pone.0164643
Guerreiro F, Seravalli E, Janssens GO, van den Heuvel-Eibrink MM, Lagendijk JJW, Raaymakers BW. Potential benefit of MRI-guided IMRT for flank irradiation in pediatric patients with Wilms’ tumor. Acta Oncol (Madr). 2019;58:243-250. doi:10.1080/0284186X.2018.1537507
Janssens GO, Melchior P, Mul J, et al. The SIOP-Renal Tumour Study Group consensus statement on flank target volume delineation for highly conformal radiotherapy. Lancet Child Adolesc Health. 2020;4:846-852. doi:10.1016/S2352-4642(20)30183-8
Mul J, Melchior P, Seravalli E, et al. Locoregional control using highly conformal flank target volumes and volumetric-modulated arc therapy in pediatric renal tumors: results from the Dutch national cohort. Radiother Oncol. 2021;159:249-254. doi:10.1016/j.radonc.2021.04.005
Mul J, van Grotel M, Seravalli E, et al. Locoregional control using highly conformal flank target volumes and volumetric-modulated arc therapy in pediatric renal tumors: Results from the Dutch national cohort. Radiother Oncol. 2021;159:249-254. doi:10.1016/j.radonc.2021.04.005
Common Terminology Criteria for Adverse Events (CTCAE) | protocol development. CTEP. Accessed September 26, 2022. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_60
Hoeben BA, Carrie C, Timmermann B, et al. Management of vertebral radiotherapy dose in paediatric patients with cancer: consensus recommendations from the SIOPE Radiotherapy Working Group. Lancet Oncol. 2019;20:e155-e166. doi:10.1016/S1470-2045(19)30034-8
Mulder RL, Kremer LCM, Hudson MM, et al. Recommendations for breast cancer surveillance for female childhood, adolescent and young adult cancer survivors treated with chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2013;14:e621-e629. doi:10.1016/S1470-2045(13)70303-6
Arunagiri N, Kelly SM, Dunlea C, et al. The spleen as an organ at risk in paediatric radiotherapy: a SIOP-Europe Radiation Oncology Working Group report. Eur J Cancer. 2021;143:1-10. doi:10.1016/j.ejca.2020.10.025
Pritchard-Jones K, Moroz V, Vujanić G, et al. Treatment and outcome of Wilms’ tumour patients: an analysis of all cases registered in the UKW3 trial. Ann Oncol. 2012;23:2457-2463. doi:10.1093/annonc/mds025
Spreafico F, Gandola L, D'Angelo P, et al. Heterogeneity of disease classified as stage III in Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Int J Radiat Oncol Biol Phys. 2012;82:348-354. doi:10.1016/j.ijrobp.2010.09.022
Reinhard H, Schmidt A, Furtwängler R, et al. Outcome of relapses of nephroblastoma in patients registered in the SIOP/GPOH trials and studies. Oncol Rep. 2008;20:463-467. doi:10.3892/or_00000029
Shamberger RC, Guthrie KA, Rehorst H, et al. Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: a report of the SIOP Renal Tumour Study Group. Pediatr Blood Cancer. 2011;56:733-737. doi:10.1002/pbc.22922
van den Heuvel-Eibrink MM, van Tinteren H, Rehorst H, et al. Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group. Pediatr Blood Cancer. 2011;56:733-737. doi:10.1002/pbc.22922
Melchior P, Dzierma Y, Rübe C, et al. Local stage dependent necessity of radiation therapy in rhabdoid tumors of the kidney (RTK). Int J Radiat Oncol Biol Phys. 2020;108:667-675. doi:10.1016/j.ijrobp.2020.04.046
Burgers JM, Tournade MF, Bey P, et al. Abdominal recurrences in Wilms’ tumours: a report from the SIOP Wilms’ tumour trials and studies. Radiother Oncol. 1986;5:175-182. doi:10.1016/s0167-8140(86)80047-0
Padovani L, Huchet A, Claude L, et al. Inter-clinician variability in making dosimetric decisions in pediatric treatment: a balance between efficacy and late effects. Radiother Oncol. 2009;93:372-376. doi:10.1016/j.radonc.2009.05.024
de Vathaire F, El-Fayech C, Ben Ayed FF, et al. Radiation dose to the pancreas and risk of diabetes mellitus in childhood cancer survivors: a retrospective cohort study. Lancet Oncol. 2012;13:1002-1010. doi:10.1016/S1470-2045(12)70323-6
Lo AC, Ronckers C, Aznar MC, et al. Breast hypoplasia and decreased lactation from radiation therapy in survivors of pediatric malignancy: a PENTEC comprehensive review. Int J Radiat Oncol Biol Phys. 2021. doi:10.1016/j.ijrobp.2021.08.032
Chargari C, Goodman KA, Diallo I, et al. Risk of second cancers in the era of modern radiation therapy: does the risk/benefit analysis overcome theoretical models? Cancer Metastasis Rev. 2016;35:277-288. doi:10.1007/s10555-016-9616-2
Nguyen F, Rubino C, Guerin S, et al. Risk of a second malignant neoplasm after cancer in childhood treated with radiotherapy: correlation with the integral dose restricted to the irradiated fields. Int J Radiat Oncol Biol Phys. 2008;70:908-915. doi:10.1016/j.ijrobp.2007.10.034